Dual Bioorthogonal Labeling of the Amyloid-β Protein Precursor Facilitates Simultaneous Visualization of the Protein and its Cleavage Products

Manuscript Number: 


Simon J. Elsässer, Manija Kazmi, Minh Nguyen Trung, Thomas P. Sakmar, Sophia Schedin-Weiss, Lars O. Tjernberg, Bengt Winblad, Lea S. van Husen


Simon J. Elsässer

  • Nothing to Disclose

Manija Kazmi

  • Nothing to Disclose

Minh Nguyen Trung

  • Nothing to Disclose

Thomas P. Sakmar

  • Nothing to Disclose
    Consulting Fees:
    I serve as a consultant and receive cash payments from two companies: RNA Smart Health, SA, and OMass, Ltd. My role is to provide scientific advice about preclinical research programs. I expect to earn between $10,000 and $20,000 per year from each company. The focus of the companies is unrelated to the present manuscript.
    I own shares of a privately held company called Anida, Inc. that was awarded for my service as a scientific advisor. The focus of the company is unrelated to the current manuscript.
    I am listed as an inventor on several U.S. patents that are unrelated to the current manuscript. I have served as an expert witness in 2014-2016 on a patent dispute unrelated to the current manuscript.
    • Agency: 
      Pfizer, Inc.
      May 1, 2019 to December 1, 2019

Sophia Schedin-Weiss

  • Nothing to Disclose

Lars O. Tjernberg

  • Nothing to Disclose

Lea S. van Husen

  • Nothing to Disclose

Bengt Winblad

  • Consulting Fees:
    I serve as scientific advisory board member in Axon, Resverlogix, Alzinova.